| 1 |
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians[J]. Arch Intern Med, 2006,166(9):1021-1026.
|
| 2 |
Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes[J]. Arch Intern Med, 2005,165(11):1280-1285.
|
| 3 |
Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs[J]. Mayo Clin Proc, 2015, 90(8):996-1000.
|
| 4 |
刘夏. 临床上超说明书用药的分析及对策[J]. 药学实践杂志,2014(6):465-468.
|
| 5 |
中华人民共和国国家卫生健康委员会. 中华人民共和国医师法(修订)[EB/OL].(2021-08-20) [2022-02-24].
|
| 6 |
Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations[J]. J Clin Epidemiol, 2013,66(7):719-725.
|
| 7 |
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008,336(7650):924-926.
|
| 8 |
Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010,182(18):E839-E842.
|
| 9 |
Glanville J, Kendrick T, McNally R, et al. Research output on primary care in Australia, Canada, Germany, the Netherlands, the United Kingdom, and the United States: bibliometric analysis[J]. BMJ, 2011,342:d1028.
|
| 10 |
陈耀龙, 罗旭飞, 史乾灵,等. 人工智能如何改变指南的未来[J]. 协和医学杂志,2021,12(1):114-121.
|
| 11 |
Gates A, Johnson C, Hartling L. Technology-assisted title and abstract screening for systematic reviews: a retrospective evaluation of the Abstrackr machine learning tool[J]. Syst Rev, 2018,7(1):45.
|
| 12 |
Simon C, Davidsen K, Hansen C, et al. BioReader: a text mining tool for performing classification of biomedical literature[J]. BMC Bioinformatics, 2019,19(Suppl 13):57.
|
| 13 |
Adams C E, Polzmacher S, Wolff A. Systematic reviews: work that needs to be done and not to be done[J]. J Evid Based Med, 2013, 6(4): 232-235.
|
| 14 |
Gates A, Guitard S, Pillay J, et al. Performance and usability of machine learning for screening in systematic reviews: a comparative evaluation of three tools[J]. Syst Rev, 2019, 8(1): 1-11.
|
| 15 |
Aljanabi M, Ghazi M, Ali A H, et al. ChatGpt: open possibilities[J]. IJCSM, 2023, 4(1): 62-64.
|
| 16 |
Qiu X, Sun T, Xu Y, et al. Pre-trained models for natural language processing: a survey[J]. Sci China Technol Sci., 2020, 63(10): 1872-1897.
|
| 17 |
Vaswani A, Shazeer N, Parmar N, et al. Attention is all you need[J]. Adv Neural Inf Process Syst, 2017, 30.
|
| 18 |
Lee J, Yoon W, Kim S, et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining[J]. Bioinformatics, 2020,36(4):1234-1240.
|
| 19 |
Palangi H, Deng L, Shen Y, et al. Deep sentence embedding using long short-term memory networks: Analysis and application to information retrieval[J]. IEEE-ACM T AUDIO SPE, 2016, 24(4): 694-707.
|
| 20 |
Xue L, Constant N, Roberts A, et al. mT5: a massively multilingual pre-trained text-to-text transformer[J]. arXiv preprint arXiv:2010.11934, 2020.
|
| 21 |
Dai Z, Wang X, Ni P, et al. Named entity recognition using BERT BiLSTM CRF for Chinese electronic health records[C]//2019 12th international congress on image and signal processing, biomedical engineering and informatics (cisp-bmei). IEEE, 2019: 1-5.
|
| 22 |
Khashabi D, Min S, Khot T, et al. Unifiedqa: crossing format boundaries with a single qa system[J]. arXiv preprint arXiv:2005.00700, 2020.
|
| 23 |
Radford A, Wu J, Child R, et al. Language models are unsupervised multitask learners[J]. OpenAI blog, 2019, 1(8): 9.
|
| 24 |
伍俊妍, 邱凯锋, 曾英彤, 等. 广东省药学会超说明书用药规范管理工作成果写入《 医师法》[J]. 今日药学, 2022,32(6):401-408.
|
| 25 |
Facts and Comparisons®: Drug Referential Resource[N/OL]. Amsterdam: Wolters Kluwer.
|
| 26 |
Nerenberg K, Zarnke K, Leung A, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children[J]. Can J Cardiol, 2018, 34(5):506-525.
|
| 27 |
中华医学会儿科学分会心血管学组,中国医师协会心血管内科医师分会儿童心血管专业委员会,中华儿科杂志编辑委员会. 儿童心力衰竭诊断和治疗建议(2020年修订版)[J]. 中华儿科杂志,2021,59(2):84-94.
|
| 28 |
Jankauskiene A, Drozdz D, Wasilewska A, et al. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase[J]. Curr Med Res Opin, 2021,37(12):2113-2122.
|
| 29 |
Bapatla K, Jankauskiene A, Drozdz D, et al. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a 6-week randomised, multicentre, double-blind study followed by open-label phase[J]. EUR HEART J, 2019, 40(s1): ehz745.0946.
|
| 30 |
Schaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age[J]. J Hypertens, 2013,31(5):993-1000.
|
| 31 |
Wells T, Blumer J, Meyers KE, et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension[J]. J Clin Hypertens (Greenwich), 2011,13(5):357-365.
|
| 32 |
Schaefer F, Litwin M, Zachwieja J, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study[J]. J Hypertens, 2011,29(12):2484-2490.
|
| 33 |
Meyers KE, Lieberman K, Solar-Yohay S, et al. The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients[J]. J Clin Hypertens (Greenwich), 2011,13(10):758-766.
|
| 34 |
Flynn JT, Meyers KE, Neto JP, et al. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years[J]. Hypertension, 2008,52(2):222-228.
|